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Abstract
Pharmacologic therapies, primarily antimuscarinic agents, have been the mainstay of treatment for
overactive bladder. These drugs produce variable efficacy, a moderate rate of side effects, and rare
occurrences of cure. The search for newer and better formulations and derivatives of this class of
medication as well as novel therapies is ongoing and primarily fueled by the high prevalence of
overactive bladder and the tremendous number of health care dollars spent on current therapy.
Surgical options for overactive bladder have evolved slowly and are currently reserved for medical
treatment failures and drug intolerance. This article will highlight the new drugs and therapies
brought into clinical use for the treatment of overactive bladder over the last few years as well as a
promising new agent in the advanced stages of development.
Introduction and context
Overactive bladder (OAB) affects between 8.0-13.9% of
the population in Western nations [1]. This variation in
prevalence is thought to be due primarily to differences
in the definition of OAB used across different study
populations. The International Continence Society has
defined OAB as ‘urgency, with or without urge incon-
tinence, usually with frequency and nocturia’ [2] in
attempts to standardize reporting of this highly prevalent
and bothersome condition. The drugs most commonly
prescribed for the treatment of OAB are the antimuscari-
nics; these drugs are proven efficacious and safe and are
the mainstay of treatment for OAB [3]. These agents
produce symptomatic improvement by reducing urgency
and therefore urge urinary incontinence (UI) and
frequency, decreasing detrusor overactivity and increas-
ing bladder capacity [4]. There are several drugs available
for use today, with some variability based on country of
residence. As newer antimuscarinic agents have become
available, some progress has been made in maximizing
therapeutic efficacy while minimizing bothersome side
effects; however, a large number of patients remain
dissatisfied with the mix of efficacy and tolerability and
discontinue therapy. Nevertheless, most physicians
prescribe a trial of antimuscarinic therapy and behavioral
modification in patients with bothersome OAB, and if it
is not effective, a second trial using a different drug or
formulation is often instituted. When these drugs fail,
the side effects become intolerable, or the category of
drug is contraindicated, physicians have limited ther-
apeutic options, including off-label use of other cate-
gories of drug or more invasive treatment options such as
neuromodulatory agents or devices.
With recent advances in the science of OAB, it has
become clear that the functioning and malfunctioning
of the urinary bladder are much more complex than
previously appreciated and that other targets besides the
muscarinic receptors should be addressed. The contin-
uous evolution and development of innovative agents
for the treatment of OAB stem from the fact that the ideal
agent – one that is lower urinary tract (LUT)-selective,
easilyadministered, andrelatively inexpensive – has yetto
be found. This search continues and therapies with
different mechanismsofaction arecurrentlybeingstudied
with some promise.
Recent advances
Several new therapies have been added to the armamen-
tarium of treatment options for OAB over the last couple
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fesoterodine, trospium extended release (ER), continued
development of novel b3 adrenergic receptor (AR)
agonists, off-label use of phosphodiesterase (PDE)
inhibitors, off-label use of intradetrusor botulinum
toxin (BTX), and advances in neuromodulation. Some
of these additions represent new drugs approved
specifically for OAB and others represent new or off-
label uses of previously approved therapies. Addition-
ally, advances in the understanding of OAB through
basic science research have not only opened the door to
new categories of drug therapy but also enhanced our
utilization of available antimuscarinics for the treatment
of OAB in the setting of bladder outlet obstruction, an
often concomitant disease process. Together, these recent
advances have had a modest impact on clinical practice.
Oxybutynin topical gel
OXY topical gel is a new transdermal formulation that is
applied once daily to the abdomen, thigh, shoulder, or
upper arm area [5]. The 1 gram application dose delivers
approximately 4 mg of drug to the circulation with stable
plasma concentrations. In a multicenter randomized
control trial (RCT), 789 patients (89% women) with
urge-predominant UI were assigned to OXY gel or
placebo once daily for 12 weeks. The mean number of
urge UI episodes, as recorded by 3-day voiding diary, was
reduced by 3.0 episodes per day versus 2.5 in the placebo
arm (P <0.0001). Urinary frequency decreased by 2.7
episodes per day and voided volume increased by 21 mL
(versus 2.0 episodes [P = 0.0017] and 3.8 mL [P =
0.0018], respectively, in the placebo group). Dry mouth
was reported in 6.9% of the treatment group versus 2.8%
of the placebo group. Skin reaction at the application site
was reported in 5.4% of the treatment group versus 1.0%
in the placebo arm. It is felt that improved skin
tolerability of the gel over the OXY transdermal patch
delivery system is secondary to lack of adhesive and skin
occlusion. The gel dries rapidly upon application and
leaves no residue; person-to-person transference via skin
contact is largely eliminated if clothing is worn over the
application site. The evolution of the transdermal gel
allows greater patient tolerability and improved com-
pliance. Further data are needed to assess whether the
decreased rate of side effects is at the expense of
diminished efficacy. This would require a head-to-head
trial with another antimuscarinic drug, a type of trial that
occurs only rarely, creating a major challenge in
evaluating the comparative efficacies of these agents.
Fesoterodine
Fesoterodine is a new oral antimuscarinic drug that is
metabolized rapidly and extensively to 5-hydroxymethyl
tolterodine (5-HMT), the same active metabolite of
tolterodine [6]. 5-HMT is metabolized in the liver, but
there is significant renal excretion without additional
metabolism, raising the possibility that 5-HMT could
also work from the luminal side of the bladder [7].
Fesoterodine is indicated for the treatment of OAB at
doses of 4 and 8 mg daily. In a multicenter, double-
blind, double-dummy RCT with tolterodine ER, 1132
patients were enrolled and received treatment [6]. The
trial showed that both the 4 and 8 mg doses of
fesoterodine were effective in improving symptoms of
OAB, with the 8 mg dose having a greater effect at the
expense of a higher rate of dry mouth. There appears to
be little difference between fesoterodine 4 mg and
tolterodine ER. Only one subject from the fesoterodine
8 mg group and one subject from the tolterodine ER
group withdrew from the study due to dry mouth. The
dose-response relationship was confirmed in another
study that pooled data from two phase III RCTs [8].
Fesoterodine 8 mg performed better than the 4 mg dose
in improving urgency and urge UI as recorded by 3-day
bladder diary, offering the possibility of dose titration.
Further studies are needed to determine whether patients
prefer the more efficacious 8 mg dose despite the added
side effects.
Trospium extended release
The development of a once-daily formulation of
trospium chloride was a necessary step to maintain its
place in the competitive antimuscarinic drug market. In
addition to convenience and improved compliance, the
ER deliver system was felt to lower maximum plasma
concentration levels of the drug and thus decrease the
incidence of side effects. Phase III data confirmed the
efficacy of the ER formulation in reducing the number of
voids per day and urge UI episodes per day [9].
Additionally, improvements in urgency severity, volume
voided, and urgency voids per day were seen. Dry mouth
incidence was 8.7% in the trospium ER group versus 3%
in the placebo group; 8.7% is the lowest reported rate of
dry mouth for this class of drug. Subsequent authors
have confirmed the improved tolerability profile of
trospium ER; constipation rates in this study were 7.5%
versus 1.8% in placebo [10]. MacDiarmid et al. [11]
tabulated an average dry mouth incidence of 20.1% with
trospium immediate release (IR) versus 10.7% with
trospium ER and average constipation rates of 9.6% with
trospium IR and 8.5% with trospium ER.
b3 adrenergic receptor agonists
It has yet to be proven whether the sympathetic nervous
system plays an active role in the filling/storage phase of
the bladder in humans; however, the presence of b ARs in
human bladder muscle prompted many attempts to
increase bladder capacity with b adrenergic stimulation.
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the human detrusor muscle contains a predominance of
b3 subtype ARs (97%) compared with b1 (1.5%) and b2
(1.4%) [12,13]. Detrusor muscle relaxation has been
found to result from b3 AR agonist therapy in animal
models; furthermore, the effect appears to result in
increased bladder capacity with no change in micturition
pressure or residual urine volume [14,15]. Several
selective b3 agonists are being evaluated in clinical trials
for the treatment of OAB. Acetanilide (YM178) was
evaluated in patients with OAB in an RCT versus
tolterodine and placebo [16]. The treatment group
experienced a significant reduction in micturition
frequency, incontinence episodes, and urgency symp-
toms as well as an increase in volume voided. The drug
was well tolerated in this study, with the most common
side effects being headache and gastrointestinal effects.
Further studies are under way to determine whether this
class of drugs is equivalent or superior to currently
available alternatives in terms of efficacy, tolerability,
and safety. These drugs are currently in the advanced
stages of development.
Phosphodiesterase inhibitors
PDE inhibitors (sildenafil, tadalafil, and vardenafil) are
generally prescribed for the treatment of erectile dysfunc-
tion (ED) and were found incidentally to improve LUT
symptoms in men [17]. LUT smooth muscle undergoes
relaxation in the presence of cyclic adenosine monopho-
sphate (cAMP) and cyclic guanosine monophosphate
(cGMP), and PDE inhibitors block the degradation of
cAMP and cGMP, resulting in greater intracellular
concentrations [18]. This class of drug is not currently
approved for the treatment of OAB or other LUT
symptoms and its use for this indication is off-label. In
an RCT evaluating the effects of sildenafil on ED and LUT
symptoms in 189 men, significant improvements in
International Prostate Symptom Score (IPSS) and health-
related quality of life (HRQoL) were seen [19]. In the first
RCT looking at sildenafil and voiding dysfunction in
women, no significant differences were seen in patients
with complete retention, partial retention, or obstructed
voiding [20]. An RCT comparing tadalafil with placebo
in 281 men with ED and LUT symptoms produced
clinically meaningful and significant symptomatic
improvement in LUT symptoms [21]. In another RCT,
vardenafil 10 mg twice daily in men with ED and LUT
symptoms showed a significant improvement in IPSS
and HRQoL [22]. The PDE-1 inhibitor vinpocetine was
evaluated in a multicenter, double-blind RCT in patients
with urgency and urge UI with urodynamically docu-
mented detrusor overactivity who failed antimuscarinic
therapy [23]. The patients received either vinpocetine
20 mg three times daily or placebo. The results showed a
significant reduction in micturition frequency in men;
however, the remainder of assessed outcomes showed a
trend toward improvement without reaching signifi-
cance. The lack of side effects in this study indicates that
the dose delivered may have been too low. While large-
scale studies in women using PDE inhibitors for OAB
have yet to be done, the early data in men suggest a
possible role in the treatment of bladder diseases. The
mechanism of action to produce this beneficial effect in
OAB remains unknown at this time.
Botulinum toxin
BTX (Botox®; Allergan, Inc., Irvine, CA, USA) is a
neurotoxin produced by Clostridium botulinum and is a
potent presynaptic inhibitor of acetylcholine release at
the neuromuscular junction. It is applied directly by
cystoscopic injection into the detrusor muscle, produ-
cing a chemical denervation that is reversible after
approximately 6 months. The mode of administration
allows high concentrations of the agent to reach the
bladder tissue without systemic administration and
resultant unsuitable levels in other organs. BTX is not
approved for the treatment of OAB but is now widely
used in patients who are refractory to conventional
antimuscarinic therapy or who do not tolerate it due to
systemic side effects.
The dose and injection protocol for BTX has not been
universally agreed upon and several variations exist. In
the initial description for the treatment of neurogenic
OAB, 300 units (U) of BTX-A was diluted in normal
saline to a concentration of 10 U/mL. Under direct
cystoscopic visualization using a 6F injection needle, 30
injections of 1 mL each were administered to the bladder
wall in 30 different locations above the trigone [24].
Since that description, several other authors have
described varying doses, dilutions, numbers of sites,
and locations (trigone, suburothelial space, and so on).
The onset of BTX-A effects is seen within the first 2 weeks
after injection [25]. Urgency, nocturia, and frequency
have been shown to improve as early as 2 days after
injection [26]. The reported duration of BTX-A following
the first injection was 6-9 months [25], and duration of
effect along with beneficial clinical effect after subse-
quent injections is maintained [27].
In a double-blind RCT including 34 patients with OAB
refractory to antimuscarinics, 200 U of BTX-A was
studied [28]. Significant improvements in maximum
cystometric capacity, frequency, and UI episodes were
seen at 4 and 12 weeks. Despite clinical improvement,
6 patients (37.5%) required clean intermittent catheter-
ization (CIC) to empty their bladder. In another RCT,
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and 15 women received placebo [29]. Approximately
60% of the women who received BTX-A reported a
clinical response with a mean duration of response of
373 days (compared with 62 days or less for placebo).
Post-void residual (PVR) urine was increased in 43% of
women in the treatment group and urinary tract
infections occurred in 75% of these women. The
duration of retention following the first injection was
approximately 2 months; however, following repeat
injection, this duration increased to 5 months.
Given the degree of voiding dysfunction seen after BTX
injection in patients with OAB, dose reduction studies
looking at 100 U have been done. In a prospective,
non-randomized study including 100 men and women,
100 U of BTX-A was injected in 30 locations [30]. At 4-
and 12-week follow-up, 88% of patients showed
significant improvement in bladder function in regard
to subjective symptoms, urodynamic parameters, and
HRQoL. There were four cases of urinary retention.
BTX appears to be a promising therapy in the treatment
of neurogenic and idiopathic OAB. Further studies are
needed to determine optimum dosages, locations, and
methods of injection. The case for usage in neurogenic
OAB patients on CIC who leak between catheterizations
seems clearer than in patients with idiopathic OAB, in
whom the PVR issue has yet to be clarified.
Neuromodulation
Sacral neuromodulation (SNM) is well established as a
treatment modality for refractory urgency, frequency,
urge UI, and idiopathic urinary retention. The mechan-
ism of action remains unknown but theories include
modulation of spinal cord reflexes and brain networks
primarily via somatic sensory afferent fibers [31]. Success
rates vary based on the technique used for placement
(with the two-stage approach having greater efficacy than
the percutaneous nerve evaluation) and the indication
for intervention (with slightly higher efficacy found
among patients with idiopathic urinary retention com-
pared with urgency/frequency and urge UI) [32].
Evolution in our understanding of neuromodulation
has allowed expanded indications for treatment and
alternative approaches for nerve stimulation. When
unilateral SNM fails, options for salvage include con-
tralateral lead placement with the potential for bilateral
stimulation or utilization of an alternative approach to
stimulation via the tibial or pudendal nerves. In
addition, previously excluded patients such as those
with neurologic diseases like multiple sclerosis or
Parkinson’s disease and patients with incomplete spinal
cord injuries have undergone successful treatment using
neuromodulation and are beginning to be recognized as
potential candidates [33,34].
One alternative approach is percutaneous tibial nerve
stimulation (PTNS), a non-invasive way of modulating
pelvic reflexes via projections from the posterior tibial
nerve [35]. Urgent® PC (Uroplasty, Inc., Minnetonka,
MN, USA) is an office procedure approved by the US
Food and Drug Administration and is used to deliver
stimulation to the posterior tibial nerve using a 34-gauge
needle electrode placed slightly cephalad to the medial
malleolus. The recommended course of treatment is
12 weekly sessions of 30 minutes each [36]. The Over-
active Bladder Innovative Therapy (OrBIT) trial was a
randomized, multicenter, control trial that compared
PTNS with tolterodine ER; 79.5% of patients in the
PTNS arm reported cure or improvement in symptoms
compared with 54.8% of the tolterodine group as
measured by the global response assessment (P =0 . 0 1 )
[35]. Objective measures, including urinary frequency,
urge UI episodes, urge severity, nighttime voids, and
volume voided, showed similar improvement in the two
groups. The authors concluded that PTNS was a ‘clinically
significant treatment alternative for OAB’.
A second alternative approach is stimulation of the
pudendal nerve within the Alcock canal by means of
neurophysiological guidance [37]. This is a logical
alternative to direct sacral root stimulations since many
of the sensory afferent fibers of the sacral nerves originate
in the pudendal nerve, which in fact innervates the pelvic
organs [38]. Peters et al. [38] reported a 71.4% response
rate (>50% improvement) in a mixed population of
patients with OAB, painful bladder syndrome, neurolo-
gic voiding dysfunction, and non-obstructive urinary
retention, of whom 52% had failed prior sacral stimula-
tion [38]. In a previous comparative study, 30 patients
underwent simultaneous sacral and pudendal lead
placement with subsequent blinded and randomized
stimulation of each electrode [39]. In 79.2% of patients,
the pudendal lead was chosen as superior, with a 63%
reduction in symptoms (versus 46% reduction with
sacral stimulation, P = 0.02).
Antimuscarinics and urinary retention
Advances in the understanding of the mechanisms of
action of antimuscarinic agents and the pathophysiology
of OAB through basic science research have enhanced
our utilization of antimuscarinics for the treatment of
OAB in the setting of bladder outlet obstruction, an often
concomitant disease process. The use of these drugs in
this setting was previously feared due to the theoretical
risk of urinary retention, and in the past there was
universal concern regarding the risk of acute retention
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Andersson and Wein [40] and Andersson et al. [41]
propose, these drugs are usually competitive antagonists,
implying that when there is massive release of acetylcho-
line during voiding, the relative effect of the drug should
be diminished. If this did not occur, urinary retention
would result from the inability of the bladder to contract.
In fact, at high doses, urinary retention can occur but this
is uncommon at the doses typically prescribed for OAB
[40]. Our current understanding is that the dose range
used for beneficial effects in OAB is much lower than that
needed to produce a significant reduction in the voiding
contraction. Monitoring PVRs in patients with prostatic
enlargement or incomplete bladder emptying is still
recommended; however, these diagnoses should not be
considered absolute contraindications to the use of
antimuscarinics.
Implications for clinical practice
Pharmacologic therapies, primarily antimuscarinic
agents, have been the mainstay of treatment for OAB.
For many patients, the side effects of oral administration
are intolerable, producing a clear demand for an agent
that bypasses first-pass metabolism in the liver. The new
OXY gel serves this purpose without the local skin effects
seen with the previously approved OXY patch. Fesoter-
odine offers another oral option to the long list of oral
agents available. Its uniqueness lies in its optimum
biopharmaceutics profile with decreased lipophilicity
and permeability across biological interfaces, producing
at least a theoretically lower incidence of side effects [42].
Additionally, there is less variability in the pharmacoki-
netics of this agent due to its metabolism by ubiquitous
non-specific esterases, allowing a more narrow thera-
peutic window. Trospium ER offers a once-daily option
with side effect rates lower than those of a previously
approved and efficacious drug. Trospium is a hydro-
philic, quaternary amine with limited ability to cross the
blood-brain barrier. This, in theory at least, should result
in minimal cognitive-related dysfunction [43]. Contra-
indications for all of these drugs include uncontrolled
narrow-angle glaucoma, urinary retention, gastric reten-
tion, or conditions with severely decreased gastrointest-
inal motility. Determining where these three new
antimuscarinic options fit among the other available
drugs in the same class is a challenge as head-to-head
trials resulting in comparative efficacies of these agents
have not been performed. As more clinical experience is
reported for drugs like PDE inhibitors and BTX for the
treatment of OAB, more practitioners are becoming
comfortable offering off-label use of these agents, thus
providing an alternative to antimuscarinic treatment.
Despite the great interest and vast number of research
studies focusing on OAB, few novel pharmaceutical
agents have made it to market, and with the exception of
BTX, there have been few surgical innovations for the
treatment of OAB. The use of expanded indications
(including patients with neurologic disease) and addi-
tional implantation routes have resulted in the successful
treatment of countless refractory OAB patients with
neuromodulation over the last couple of years. Neuro-
modulation is considered ineffective and thus contra-
indicated in patients with complete spinal cord injury.
Ongoing scientific research has provided us with greater
sophistication and a clearer understanding of the
mechanisms of therapeutic interventions for OAB and
this should inevitably translate to more refined and
directed therapies in the future. There are several classes
of drug currently in phase II and phase III testing which
may have a great impact on the treatment of OAB in
upcoming years.
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